相似文献
1
Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
Antimicrob Agents Chemother. 2004 Jun;48(6):2140-3. doi: 10.1128/AAC.48.6.2140-2143.2004.
2
Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Antimicrob Agents Chemother. 2006 Jun;50(6):2122-31. doi: 10.1128/AAC.00315-06.
3
Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2007 Apr;51(4):1253-8. doi: 10.1128/AAC.01449-06. Epub 2007 Jan 29.
4
Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Arzneimittelforschung. 1996 Jul;46(7):711-5.
5
Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Antimicrob Agents Chemother. 2006 Feb;50(2):674-84. doi: 10.1128/AAC.50.2.674-684.2006.
6
Liposomal and lipid-based formulations of amphotericin B.
Leukemia. 1996 Jun;10 Suppl 2:s93-6.
7
Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
J Antimicrob Chemother. 1992 Sep;30(3):353-63. doi: 10.1093/jac/30.3.353.
8
The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Oncol Nurs Forum. 1998 Jan-Feb;25(1):35-48.
9
Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
J Pharm Pharm Sci. 2003 May-Aug;6(2):231-7.
10
Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Drugs. 1998 Sep;56(3):365-83. doi: 10.2165/00003495-199856030-00008.
引用本文的文献
1
Coccidioidomycosis: A Contemporary Review.
Infect Dis Ther. 2022 Apr;11(2):713-742. doi: 10.1007/s40121-022-00606-y. Epub 2022 Mar 1.
2
Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis.
Pathogens. 2021 Oct 12;10(10):1303. doi: 10.3390/pathogens10101303.
3
The Rise of : Forces Against the Dust Devil Unleashed.
Front Immunol. 2019 Sep 11;10:2188. doi: 10.3389/fimmu.2019.02188. eCollection 2019.
4
Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.02293-17. Print 2018 Jul.
5
Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
Antimicrob Agents Chemother. 2008 Jan;52(1):259-68. doi: 10.1128/AAC.00870-07. Epub 2007 Oct 29.
本文引用的文献
1
A comparative review of conventional and lipid formulations of amphotericin B.
J Clin Pharm Ther. 1999 Aug;24(4):249-57. doi: 10.1046/j.1365-2710.1999.00220.x.
2
Lipid formulations of amphotericin B: clinical efficacy and toxicities.
Clin Infect Dis. 1998 Sep;27(3):603-18. doi: 10.1086/514704.
3
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Clin Infect Dis. 1998 Jun;26(6):1383-96. doi: 10.1086/516353.
4
Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.
Antimicrob Agents Chemother. 1998 Apr;42(4):899-902. doi: 10.1128/AAC.42.4.899.
5
Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
Leuk Res. 1997 Mar;21(3):183-8. doi: 10.1016/s0145-2126(96)00075-6.
6
Diversity of lipid-based polyene formulations and their behavior in biological systems.
Eur J Clin Microbiol Infect Dis. 1997 Jan;16(1):81-92. doi: 10.1007/BF01575125.
7
Biopharmaceutical aspects of lipid formulations of amphotericin B.
Eur J Clin Microbiol Infect Dis. 1997 Jan;16(1):64-73. doi: 10.1007/BF01575123.
8
Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials.
Clin Infect Dis. 1996 May;22 Suppl 2:S145-7. doi: 10.1093/clinids/22.supplement_2.s145.
9
Lipid formulations of amphotericin B: recent progress and future directions.
Clin Infect Dis. 1996 May;22 Suppl 2:S133-44. doi: 10.1093/clinids/22.supplement_2.s133.
10
Efficacy of AmBisome in murine coccidioidomycosis.
J Med Vet Mycol. 1994 Dec;32(6):467-71. doi: 10.1080/02681219480000621.
Zotero 插件